M&A Deal Summary

Hospira Acquires Mayne Pharma

On October 20, 2006, Hospira acquired healthcare services company Mayne Pharma for 2.0B USD

Acquisition Highlights
  • This is Hospira’s 2nd transaction in the Healthcare Services sector.
  • This is Hospira’s largest (disclosed) transaction.
  • This is Hospira’s 1st transaction in Australia.

M&A Deal Summary
Date 2006-10-20
Target Mayne Pharma
Sector Healthcare Services
Buyer(s) Hospira
Deal Type Add-on Acquisition
Deal Value 2.0B USD

Target

Mayne Pharma

Melbourne, Australia
Mayne Pharma Ltd, an Australia-based specialty injectable pharmaceuticals company.

Search 200,066 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Hospira

Lake Forest, Illinois, United States
Category Company
Founded 2003
Sector Life Science
Employees19,000
Revenue 4.5B USD (2014)
DESCRIPTION

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. Hospira, Inc. is based in Lake Forest, Illinois.

DEAL STATS #
Overall 2 of 8
Sector (Healthcare Services) 2 of 3
Type (Add-on Acquisition) 2 of 4
Country (Australia) 1 of 2
Year (2006) 1 of 2
Size (of disclosed) 1 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-08-01 Physiometrix

Billerica, Massachusetts, United States

Physiometrix, Inc. designs, manufactures and markets non-invasive medical products -- based on novel gel materials, sophisticated signal-processing electronics technologies, and proprietary software -- for use in anesthesia monitoring during surgical procedures and in other medical settings, including the intensive care unit. The company generated approximately $1.9 million in 2004 sales at the wholesale level primarily through a distribution agreement.

Buy $23M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-10-31 BresaGen

Adelaide, Australia

BresaGen Ltd. is a biotechnology company that develops protein and peptide therapeutics.

Buy $17M
Mergr

Product

Company

Legal